Shares of US biotech Momenta Pharmaceuticals (Nasdaq: MNTA) raced up 70% to $52.44 in pre-market trading this morning, after it was revealed that it had agree to be acquired by healthcare giant Johnson & Johnson (NYSE: JNJ).
Under the definitive agreement, J&J will buy the company in an all cash transaction for $52.50 per share, representing a total equity value of $6.5 billion and a 70% premium to Momenta’s closing price on August 18, 2020
This acquisition provides an opportunity for the J&J Janssen Pharmaceutical Companies to broaden leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze